Through its strategic alliance with the FOCUS Group, Germany, AVICENNA has assembled a unique core expertise in global drug development and commercialisation.  It will leverage this expertise to build a sophisticated and highly efficient drug development and commercialisation “Drug Development Engine”.  This engine will drive in-licensed compounds through to clinical proof-of-concept. The resulting product will then be out-licensed to international big pharma partners within 2-3 years in return for substantial initial upfront payments, milestone payments and royalties resulting from sales.

The generation of early revenue streams will allow AVICENNA to continuously expand and complement its product portfolio through in-licensing of drug development candidates in late pre-clinical and early clinical development. Speed is achieved by strategically leveraging existing and readily available drug discovery, drug development and commercialisation resources.

Thus, AVICENNA will become a world-class Bio-Pharmaceutical company from a foundation that is characterised by the unparalleled results in efficiency, flexibility and scalability resulting from this innovative business model.